AstraZeneca, a leading biopharmaceutical company, has further developed its Global Capability Centre (GCC) in Bengaluru with a new facility, which involves an investment of Rs.166 crore.

The enhanced hub will have the capacity to support nearly 1,300 employees, bringing about the creation of 400 additional jobs.

This development represents AstraZeneca’s second significant investment in India within the past year, following the expansion of its Global Innovation and Technology Centre (GITC) in Chennai.

Combined, AstraZeneca India Private Limited’s (AZIPL) operations in the country now employ nearly 4,000 individuals.

AstraZeneca (AZN.L) and its collaborator Daiichi Sankyo (4568.T) have received approval from US regulatory authorities for their precision medicine, Datroway, aimed at treating a specific type of lung cancer, which represents the first approval of this therapy for this indication and increases access for patients. 

Also Read: The Sun Tzu Way of Ladder Ascender to Industry Leader

Datroway has been authorized in the United States, the largest pharmaceuticals market globally, for use in adults with advanced non-small cell lung cancer who have previously undergone treatment, AstraZeneca announced earlier, highlighting it as the first therapy of its kind to be approved in the country for lung cancer. 

Datroway is part of a category of medications termed antibody-drug conjugates, often referred to as guided-missiles since they are engineered to specifically target cancer cells while avoiding damage to healthy cells, in contrast to traditional chemotherapy. 

 

It functions by targeting the TROP2 protein present on the surface of tumor cells in various cancer types, and it is already approved for a specific form of breast cancer. 

AstraZeneca and Japan's Daiichi have maintained a long-term partnership for the development of cancer treatments, initially starting with Enhertu, followed by a 2020 agreement to co-develop and commercialize Datroway, valued at up to $6 billion.

Also Read: Circular Economy: How to Hack the $4.5 Trillion Opportunity?

The Anglo-Swedish pharmaceutical company announced on Tuesday it would disburse $45 million to Daiichi in milestone-related payments in light of the US approval.